Volume Alert - OREX 5.68 Orexigen Therapeutics $OREX Hit a

New Post Public Reply Private Reply Replies (0) Message Board
leahanne
Volume Alert - OREX 5.68 Orexigen Therapeutics $OREX Hit a high today of 5.76 Closing the day 10:30 at 5.68 +0.64 +12.70% With a day low of 5.01 and a total volume of 3,144,502.

OREX Recent Posts: http://investorshangout.com/Orexigen-Therapeu...REX-55007/

OREX Orexigen Therapeutics Recent Headline News

Nasdaq stocks posting largest percentage increases
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
ICUI: 82.85 (+1.98), OREX: 6.02 (+0.98), PCMI: 8.60 (-0.30), CYAN: 5.92 (-0.14), ACHN: 13.28 (+0.80), TGTX: 13.04 (+0.13), AGIO: 88.12 (+6.21), LIOX: 5.36 (-0.07), SAJA: 6.25 (+0.65), PLNR: 7.05 (+0.24)

Bel-Phen Pilot Study News, Hold On To Your Shares
Rx Stocks - at Seeking Alpha - Tue Nov 11, 12:13PM CST

OREX: 6.02 (+0.98), VVUS: 3.26 (-0.01), ARNA: 4.57 (+0.08)

Uptrend Call Working As Orexigen Therapeutics Stock Rises 23.6% (OREX)
Comtex SmarTrend(R) - Tue Nov 11, 11:04AM CST
SmarTrend identified an Uptrend for Orexigen Therapeutics (NASDAQ:OREX) on October 17th, 2014 at $4.16. In approximately 4 weeks, Orexigen Therapeutics has returned 23.56% as of today's recent price of $5.14.
OREX: 6.02 (+0.98)

Orexigen Turns Around with Q3 Earnings Beat, Shares Soar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 10:20AM CST
Orexigen (OREX) swung to profit in the third quarter of 2014 with earnings of 9 cents per share beating the Zacks Consensus Estimate of 5 cents.
OREX: 6.02 (+0.98), VVUS: 3.26 (-0.01), AMAG: 34.70 (-0.18)

Orexigen (OREX) Worth Watching: Stock Soars 33.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 8:25AM CST
Orexigen (OREX) was a big mover last session, with shares surging over 33% on the day.
BIIB: 319.78 (-4.81), OREX: 6.02 (+0.98), AMAG: 34.70 (-0.18), AFFX: 9.50 (+0.08)

Why Orexigen Therapeutics, Inc. Stock Skyrocketed
Sean Williams, The Motley Fool - Motley Fool - Mon Nov 10, 5:52PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Orexigen Therapeutics , a...
OREX: 6.02 (+0.98), VVUS: 3.26 (-0.01), ARNA: 4.57 (+0.08)

Look for Shares of Orexigen Therapeutics to Potentially Pullback after Yesterday's 33.25% Rise
Comtex SmarTrend(R) - Mon Nov 10, 5:24PM CST
Orexigen Therapeutics (NASDAQ:OREX) traded in a range yesterday that spanned from a low of $4.04 to a high of $5.33. Yesterday, the shares gained 33.2%, which took the trading range above the 3-day high of $4.08 on volume of 15.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
OREX: 6.02 (+0.98)

Market News: Apple,FireEye, Orexigen Therapeutics
at The Street - Mon Nov 10, 4:17PM CST
Oppenheimer market strategist, John Stoltzfus estimated that the S&P 500 could reach as 2,080 pointsThe stock markets in the United States ended the trading session higher as investors speculated that...
OREX: 6.02 (+0.98), FEYE: 32.66 (-0.19), AAPL: 110.63 (+0.93)

Dean Foods and Toll Brothers are big market movers
AP - Mon Nov 10, 3:48PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:
DVAX: 16.15 (-0.45), OREX: 6.02 (+0.98), RYN: 26.31 (-0.42), MRK: 59.26 (-0.11), CMCSK: 53.27 (+0.49), DF: 16.48 (+0.21), TOL: 33.81 (+0.09), CMCSA: 53.41 (+0.45)

Orexigen Therapeutics (OREX) Stock Continues to Rise as EU Reviews Contrave Drug
at The Street - Mon Nov 10, 1:53PM CST
Orexigen Therapeutics (OREX) stock is up after the company said the European Union review of its drug is progressing, as it reported better than expected third quarter earnings this morning.
OREX: 6.02 (+0.98)

Arena And Vivus Investors Need To Watch Orexigen
Spencer Osborne - at Seeking Alpha - Mon Nov 10, 12:24PM CST

OREX: 6.02 (+0.98), VVUS: 3.26 (-0.01), ARNA: 4.57 (+0.08)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 11:59AM CST

UCP: 11.43 (-0.27), JRJC: 7.40 (-0.09), NAVB: 1.01 (-0.01), SANW: 3.44 (-0.07), PLPM: 1.68 (-0.07), RYN: 26.31 (-0.42), INFU: 2.92 (-0.01), LIOX: 5.36 (-0.07), DY: 27.59 (-0.60), MTZ: 24.41 (-0.40), CGIX: 6.44 (-0.06), MUX: 1.38 (+0.04), OREX: 6.02 (+0.98), URRE: 2.46 (-0.05), ACHN: 13.28 (+0.80), REN: 2.58 (-0.12), MPO: 3.19 (+0.05), AKBA: 10.77 (+0.41), TRX: 1.09 (+0.03), PLNR: 7.05 (+0.24)

Stock to Watch: Orexigen Therapeutics Up 19.5% (OREX)
Comtex SmarTrend(R) - Mon Nov 10, 11:27AM CST
Orexigen Therapeutics (NASDAQ:OREX) is one of today's best performing low-priced stocks, up 19.5% to $4.60 on 1.1x average daily volume. Orexigen Therapeutics has traded 3.6 million shares thus far today, vs. average volume of 3.3 million shares per day. The stock has outperformed the Dow (19.5% to the Dow's 0.1%) and outperformed the S&P 500 (19.5% to the S&P's 0.3%) during today's trading.
OREX: 6.02 (+0.98)

Orexigen Therapeutics' (OREX) CEO Mike Narachi on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 10:51AM CST

OREX: 6.02 (+0.98)

Orexigen ups earnings by 161% in Q3
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 10:16AM CST

OREX: 6.02 (+0.98)

Orexigen rises as weight loss drug review proceeds
AP - Mon Nov 10, 10:02AM CST
NEW YORK (AP) — Shares of Orexigen Therapeutics Inc. jumped Monday after the company said a European Union review of its weight loss drug Contrave, which was approved in the U.S. in September, is progressing on schedule.
OREX: 6.02 (+0.98), VVUS: 3.26 (-0.01), ARNA: 4.57 (+0.08)

Orexigen Therapeutics (OREX) Stock Soars Today on Big Third Quarter Earnings Beat
at The Street - Mon Nov 10, 9:33AM CST
Orexigen Therapeutics (OREX) stock is skyrocketing this morning after the company posted higher than expected third quarter earnings.
OREX: 6.02 (+0.98)

Orexigen Beats The Street On Milestone Payments
Spencer Osborne - at Seeking Alpha - Mon Nov 10, 8:21AM CST

OREX: 6.02 (+0.98)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 8:14AM CST

PT: 1.77 (+0.06), GPRO: 77.46 (+2.46), OREX: 6.02 (+0.98), GOGO: 18.75 (+0.56), JRJC: 7.40 (-0.09), UEC: 1.78 (-0.02), ACHN: 13.30 (+0.82), ARQL: 1.20 (+0.05), CMCM: 18.67 (+0.65), IBIO: 1.16 (+0.01), DF: 16.48 (+0.21)

Orexigen Therapeutics (OREX) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Nov 10, 7:25AM CST

OREX: 6.02 (+0.98)

Orexigen Therapeutics (OREXQ) Stock Research Links

OREXQ Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Endava's Stock Tumble Sparks Investor Class Action

Updated Category News Views 2

A Rocky Day for Endava Investors Here's the thing, on September 21, 2026, Endava plc hit a rough patch that left a mark. After the market closed, the company announced that it had put its Chief Financial Officer, Mark Thurston, on administrative leave. This wasn't just a routine shuffle; it came on the heels of the Board's Audit Committee finding reason to probe into...

Continue Reading
CorePower Yoga Expands in Miami with New Studios

Updated Category News Views 9

Greasing the Wheels of Miami's Wellness Scene If you're living under a rock, you might not have noticed, but CorePower Yoga is making some serious moves in Miami. We're talking about two new studios opening their doors: one in Midtown Miami, already rolling out the mats as of October 19, and another flagship joint soon to hit Coral Gables. Clearly, they see the demand for...

Continue Reading
Geothermal Energy Gets Boost with GRMS Adoption

Updated Category News Views 4

Geothermal's Big Leap with the GRMS The oil and gas sector didn't explode overnight—it leapt due to a consistent, standardized language that spoke to investors like a charm. Now, the geothermal industry is borrowing a page from this book of success with the Geothermal Resources Management System (GRMS). Finally, a framework not just built on hope and hot air, but...

Continue Reading
Call to Action: Make Disease Cure the Top Election Issue

Updated Category News Views 3

A Call for Congressional Accountability The American Center for Cures is banging the drum for change, and they're banging it loud. Founded by Lou Weisbach, this group has come out swinging, urging Americans to slap disease onto the ballot in the midterms. Why? Because dealing with Alzheimer's, diabetes, heart disease, and cancer every year rips a whopping $1.1 trillion...

Continue Reading
Norwegian Bella™: A New Era in Luxury Cruising

Updated Category News Views 5

Setting Sail with Norwegian Bella™ in 2028 When you hear about another cruise ship hitting the water, eye rolls might come naturally. But Norwegian Cruise Line's latest announcement adds a few twists worth noting. Today, the big news is that the Norwegian Bella™, the freshest face in NCL's innovative Prima Class, is now open for bookings. This beauty will start its...

Continue Reading
NSSF Battles NM's Unconstitutional Gun Law in Court

Updated Category News Views 6

Taking Shots at New Mexico's Gun Laws You've got the National Shooting Sports Foundation (NSSF) heading back into the legal trenches. Fresh lawsuit filed, they're targeting New Mexico's Attorney General, Raúl Torrez, for trying to keep a seven-day "cooling off" period intact that they've already been told is unconstitutional. Look, this ain't their first rodeo with this...

Continue Reading
Zika Virus: A Surprising Ally in Brain Cancer Fight

Updated Category News Views 9

Here’s something you don’t hear every day: using a virus that typically targets the brain not as a foe, but as a formidable ally in the war against glioblastoma. It’s a gutsy play by UP Oncolytics, a scrappy biotech outfit cradled within Rosalind Franklin University’s Helix 51 incubator. Risky Bet on a Known Adversary Glioblastoma—a real beast in the cancer...

Continue Reading
AI Agents Race: 10M Downloads Spark Competitive Fire

Updated Category News Views 4

The AI Agent Arms Race is On Throwdown time in the AI jungle, folks. A new AI agent hit the big 10.9 million downloads in a mere six weeks. In the digital world, those kinds of numbers are the equivalent of finding a unicorn in your backyard. This data gem comes courtesy of Sensor Tower, as reported by Yahoo Finance, and it looks like the appetite for this technological...

Continue Reading
Parents as Teachers Podcast: Anthem Awards Finalist

Updated Category News Views 4

Celebrating Impact Through Parenthood Narratives Blending heartfelt stories with educational insights, the Parents as Teachers Podcast stands tall as a Finalist in two categories of the 6th Annual Anthem Awards. Recognizing achievements in Content & Media for both Education, Art & Culture and Health, this nod acknowledges the profound impact being made on family...

Continue Reading
PrecisePK Celebrates 40 Years of Revolution in Dosing

Updated Category News Views 1

Forty Years of Changing the Game There’s something to be said for sticking around in an industry for four decades. PrecisePK, a name that's become synonymous with precision dosing, has been revolutionizing how pharmacists do their jobs since 1985. This isn’t just a company resting on its laurels; it’s at the forefront of technological integration in healthcare....

Continue Reading

Top 5 Most Recently Viewed Articles

Abeona Therapeutics Achieves Milestones with ZEVASKYN Launch

Updated Category News Views 109

Abeona Therapeutics Financial Overview and Recent Progress Abeona Therapeutics Inc. has recently made significant strides with the launch of ZEVASKYN™, a groundbreaking therapy. This innovative treatment is designed to address the urgent medical needs of patients suffering from recessive dystrophic epidermolysis bullosa (RDEB). With the FDA's approval, the company is on...

Continue Reading
Projected Growth of Monk Fruit Sweeteners Market Through 2032

Updated Category News Views 133

Monk Fruit Sweeteners Market Growth Overview The monk fruit sweeteners market is witnessing a significant transformation, spurred by health-conscious consumers seeking natural alternatives to sugar. This market is projected to experience a steady growth trajectory, reaching a remarkable $147.2 million by 2032. The expected compound annual growth rate (CAGR) is estimated...

Continue Reading
Discover Ultimate Luxury and Marine Animal Adventures in San Diego

Updated Category News Views 175

Experience Luxury in San Diego San Diego has long been known for its stunning coastlines, vibrant culture, and world-class attractions. Visitors seeking a once-in-a-lifetime getaway can book the Ultimate San Diego VIP Getaway Package. This exclusive offering combines luxury, adventure, and unforgettable experiences designed to pamper guests in a seamless and enjoyable...

Continue Reading
7 Easy-to-Miss Issues That Might Be Slowing Down Your Manufacturing Operations

Updated Category Business Views 156

Every manufacturing business wants the same things. Orders moving on schedule. Machines staying busy. Teams hitting production targets. But sometimes, even when you do all the right things, output slips. People stay busy all day. Yet somehow, less work gets done. And you can’t pinpoint why. The biggest slowdowns don’t announce themselves. They build up over time. They...

Continue Reading
Made-in-China.com's Impactful Exhibition at BIG 5 Global Event

Updated Category News Views 124

Made-in-China.com Showcases Chinese Suppliers at BIG 5 Global Recently, a remarkable event unfolded at the BIG 5 Global, which took place in Dubai. Made-in-China.com highlighted the talents of 15 prominent Chinese suppliers, showcasing their innovative construction materials aimed at enhancing urban development and infrastructure across the globe. This significant...

Continue Reading